The high-stakes rollout of Sanofi's dengue vaccine, Dengvaxia, is slated this month in the private market, the lead executive for the product said, adding that a tender for 3 million doses is in advanced discussions in the Philippines for a public launch within weeks.
The China Food and Drug Administration (CFDA) said in a recent report that the country's food and drug safety industry has improved and that cases of illegal or bad drugs fell in 2015 compared to 2014.
Tokyo-based Eisai said it will start selling active pharmaceutical ingredients to domestic generic makers and will invest "tens of millions of dollars" to scale up production at its India plant in Andhra Pradesh.
With approval for Tresiba in China potentially years out, Novo Nordisk expects continued price competition from domestic companies that will show up on the books more widely in the coming year and into 2017.
China Resources Pharmaceutical Group, part of the state-owned mega-corporation China Resources, is planning to tap the capital markets in Hong Kong for a $1 billion initial public offering, according to a report by Reuters.
GlaxoSmithKline saw another sharp drop in China sales of established pharmaceuticals, but CEO Andrew Witty said that was all part-and-parcel of reshaping the business including sales of products in the Middle Kingdom and that 2016 should start to see a turnaround, along with emerging markets generally.
China once again aided AstraZeneca, with the full-year sales up 15%, the same pace as Latin America, and up 10% on the fourth quarter.
A $774 million deal Hong Kong-listed Sino Biopharmaceutical planned to make by buying a stake in a Chinese asset management company has been axed by Sino after markets around the world have fallen, especially in China.
Beijing-based Sinovac Biotech is in play, with the board getting an unsolicited offer of $7 a share from a consortium of Chinese drug and investment firms, placing it 13% above a management-led offer of $6.18 a share days before for a firm that has a small, but growing, vaccine business in China.
China-focused SciClone Pharmaceuticals is reviewing a range of "strategic alternatives" to enhance shareholder value fresh off a settlement with the U.S. Securities and Exchange Commission on possible violations of the Foreign Corrupt Practices Act, or FCPA.